Inder Singh

2 weeks ago | ophthalmologytimes.com | Inder Singh |Sheryl Stevenson |Hattie Hayes

Inder Paul Singh, MD, glaucoma and anterior segment surgeon from southeastern Wisconsin, presented early data on a novel one-step limited vitrectomy device designed for the removal of symptomatic vitreous opacities (CSVO) in pseudophakic patients.

Sep 13, 2024 | jmedicalcasereports.biomedcentral.com | Inder Singh |Sri Krishna

A 66-year-old male, farmer by profession, Punjabi Hindu by ethnicity, a reformed smoker with a known case of COPD, presented in September 2023 with a history of fever for 5 days. History of 15-day breathlessness in modified medical research council  grade 4, associated with cough and expectoration was there. History of unintentional, unquantified weight loss for 15–20 days.

Aug 31, 2024 | optometrytimes.com | Melissa Tawa |Deborah Ristvedt |Inder Singh |Arsham Sheybani

August 31, 2024By In this episode, four expert faculty talk about the importance of early diagnosis and treatment of thyroid eye disease. They discuss the differential diagnosis, screening tests, and the need for multidisciplinary management for these patients. Glaucoma remains a leading cause of irreversible blindness globally as progressive optic nerve damage leads to permanent vision loss.

May 7, 2024 | optometrytimes.com | Inder Singh |David Hutton |Sheryl Stevenson

May 7, 2024Inder Paul Singh, MD, defines what it means to have an interventional mindset when it comes to glaucoma procedures and treatments during the Controversies in Modern Eye Care 2024 meeting. Having an interventional mindset when it comes to glaucoma treatment can save the patient time by finding the procedure or medication that is right for them, according to Inder Paul Singh, MD.

Jan 1, 2024 | glaucomaphysician.net | Inder Singh

This article was originally published in a sponsored newsletter. I was an investigator in the standalone pivotal trials for the iStent infinite (Glaukos) approval and was encouraged by the positive outcomes. We found that 70% of patients had a 20% or more reduction in intraocular pressure (IOP) and 50% had a reduction of 30% or more. These patients were advanced enough to have had two failed surgeries, were on an average of three topical medications, or both.